Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2025-12-27 @ 11:59 PM
Study NCT ID:
NCT06901934
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-03-30
First Post:
2025-03-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 40}, 'targetDuration': '2 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2025-10-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-03', 'completionDateStruct': {'date': '2028-10-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-03-24', 'studyFirstSubmitDate': '2025-03-24', 'studyFirstSubmitQcDate': '2025-03-24', 'lastUpdatePostDateStruct': {'date': '2025-03-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2025-03-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-10-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The response to neoadjuvant chemotherapy in muscle invasive bladder cancer in relation to JAM3 expression', 'timeFrame': 'from enrollment to the end of treatment at 5 months'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Urothelial Carcinoma Bladder']}, 'referencesModule': {'references': [{'pmid': '39586489', 'type': 'BACKGROUND', 'citation': 'Steiner L, Eldh M, Offens A, Veerman RE, Johansson M, Hemdan T, Netterling H, Huge Y, Abdul-Sattar Aljabery F, Alamdari F, Liden O, Sherif A, Gabrielsson S. Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer. Cancer Lett. 2025 Jan 28;609:217352. doi: 10.1016/j.canlet.2024.217352. Epub 2024 Nov 23.'}]}, 'descriptionModule': {'briefSummary': "Bladder cancer(BC) is the 10th most common cancer globally, with a higher incidence in males than females, being the 6th most common cancer in men with high mortality, causing a societal burden worldwide.\n\nKnown risk factors include age, gender, cigarettes, genetic factors, and other environmental influences .\n\nBC can be classified into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) . MIBC exhibits a more aggressive nature, correlates with a higher level of T-stage, and has more significant genetic heterogeneity .\n\nDespite comprehensive treatment regimens comprising neoadjuvant chemotherapy, radical cystectomy (RC) and adjuvant immunotherapies, a significant proportion of MIBC patients continue to progress to more advanced stages with limited clinical indicators.\n\nUnfortunately, the mechanisms underlying BC initiation, proliferation, and progression remain largely unknown.\n\nThe occurrence of genetic alterations is believed to be closely linked to BC tumorigenesis. Therefore, investigating the genetic alterations might offer opportunities to further understand biological changes in BC .\n\nA key mechanism underlying tumor progression and metastasis is the epithelial-mesenchymal transition (EMT), which is associated with increased invasiveness, chemoresistance, and immune evasion.\n\nEMT is characterized by the downregulation of epithelial markers such as E-cadherin (CDH1) and the upregulation of mesenchymal markers like N-cadherin (CDH2), vimentin, Snail, and ZEB proteins .\n\nEmerging evidence suggests that junctional adhesion molecule 3 (JAM3) plays a role in EMT and cancer progression, with documented involvement in gastric cancer.\n\nHowever, its significance in MIBC remains poorly understood. Investigating JAM3 expression in MIBC may provide novel prognostic insights and help refine patient stratification for NAC and immunotherapy.\n\nAim:\n\nThis study aims to analyze JAM3 expression in transurethral biopsies from MIUC patients and correlate it with:\n\n* Tumor aggressiveness (grading, staging, and histological features).\n* Response to neoadjuvant chemotherapy .\n* Patient survival and disease progression.\n\nThis study will provide a better understanding of JAM3's role in EMT and MIUC progression, offering potential biomarker-driven insights for treatment stratification.\n\nIf JAM3 is validated as a prognostic factor, it could guide personalized therapeutic approaches and optimizing NAC outcomes."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': ':Patients diagnosed with muscle invasive urothelial carcinoma( MIUC) and eligible for neoadjuvant chemotherapy( NAC)', 'eligibilityCriteria': 'Inclusion criteria\n\n1. Patients above 18 years\n2. Histopathological confirmed TCC\n3. Patients with MIBC\n4. Patients eligible for neoadjuvant chemotherapy\n\nExclusion criteria\n\n1. Patients with metastatic disease\n2. Patients ineligible for systemic therapy'}, 'identificationModule': {'nctId': 'NCT06901934', 'briefTitle': 'JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes', 'organization': {'class': 'OTHER', 'fullName': 'Assiut University'}, 'officialTitle': 'JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response and Survival Outcomes', 'orgStudyIdInfo': {'id': 'JAM3 biomarker bladder cancer'}}, 'armsInterventionsModule': {'interventions': [{'name': 'junctional adhesion molecule3 expression by immunhistochemistry', 'type': 'OTHER', 'description': '* Data record of patient will be reviewed for the following:\n* Clinical features:\n* Age\n* Performance status\n* Risk factors(smoking,stones or bilharziasis)\n* Comorbidities\n* Family history\n* Pathological features:\n* Histological subtype\n* Grade\n* Muscle invasion\n* Carcinoma in situ\n* Immunohistochemistry(IHC):\n\nJAM3 expression by IHC\n\n* TNM staging\n* Number of chemotherapy cycles received\n* Radical surgery or\n* CCRT and type of concurrent\n* Post treatment histological response\n* . Follow-Up and Survival Analysis:\n* During treatment: Monitoring for adverse events of chemotherapy and clinical response.\n* After treatment: Imaging and clinical examination every 3 months for 2 years.\n* Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS)..'}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'zienab yahia', 'role': 'CONTACT', 'email': 'zienab959@gmail.com', 'phone': '20 01060399770'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Zeinab Yahia Zaki', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'zeinab yahia zaki', 'investigatorFullName': 'Zeinab Yahia Zaki', 'investigatorAffiliation': 'Assiut University'}}}}